A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
about
Muscle-invasive urothelial bladder cancer: an update on systemic therapyRole of HER2 in NSCLCAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceFrequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.HER2 somatic mutations are associated with poor survival in HER2-negative breast cancersA randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of originCharacterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.Novel molecular targets for urothelial carcinomaMorphological and molecular characteristics of HER2 amplified urothelial bladder cancerHER2 as a target in invasive urothelial carcinoma.Captured metagenomics: large-scale targeting of genes based on 'sequence capture' reveals functional diversity in soils.Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.The clinical significance of HER2 protein amplification/expression in urinary bladder lesion.Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder CancersConsensus and conflict in invasive micropapillary carcinoma: a case report and review of the literature.Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinomaIntrinsic basal and luminal subtypes of muscle-invasive bladder cancer.Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancerTargeting Signaling Transduction Pathways in Bladder Cancer.Systemic therapy for metastatic bladder cancer in 2016 and beyond.Lipid Cell and Micropapillary Variants of Urothelial Carcinoma of the Ureter.Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinomaComparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.Characteristics and clinical significance of histological variants of bladder cancer.Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Enhanced cellular uptake and tumor penetration of nanoparticles by imprinting the "hidden" part of membrane receptors for targeted drug delivery.Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.HER kinase inhibition in patients with HER2- and HER3-mutant cancers.A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.Intratumoral Heterogeneity of ERBB2 Amplification and HER2 Expression in Micropapillary Urothelial Carcinoma.Bladder cancer.Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq.ATM/RB1 mutations predict shorter overall survival in urothelial cancer.Unmasking molecular profiles of bladder cancer.
P2860
Q26775780-21E4322B-BB32-4BB8-91E2-78B2F8C52978Q26781683-3F30AFED-BCCC-4ADF-94D0-D10443DB1886Q26797471-38DFB897-0878-4E1D-9943-7CD0E084E94EQ33583057-B5FC1B87-1686-4048-8E1C-F604E9C6B81BQ33607579-8ED029CB-8143-4A21-84BE-9D3A9B21BEA4Q34081624-7AA883A5-0F20-4001-AEAD-1265E5652A83Q34959996-E4CCDEE8-D9A4-4183-A129-2044BC17EF5DQ35234108-A1F5744D-0453-4A9E-94A8-BDB6CFDDEB4DQ35527068-805AB1D1-76C5-4DBC-AF4F-CEFA876D203DQ35698114-9D7B5916-3814-4CB4-80CE-F01D49B99A8FQ35755382-5A64242A-8172-4C5A-81F1-D76181BDBD45Q35816844-AF800BD1-15CC-4806-8483-C89595AECD14Q35864528-95702AA0-4DEF-4DE2-962E-BA0C436C822DQ36034067-799214D1-BAA3-460B-94DD-5664054BD540Q36192868-382AC4F3-7937-454F-83D9-7DB8C61E5E39Q36666214-FE5C514A-8437-403E-910C-1E8E0E1AE87AQ37588485-5C9E8410-EC92-4FBA-974D-CB7F9DF1445BQ38222834-FA357FD3-9300-4D69-B4D8-396B906E4002Q38269990-C543AE8E-4576-4F51-ACD1-26BC1E5D42BCQ38608540-AB43609D-EEF2-4DD6-896F-74A41C1F2EE4Q38753358-065A6658-B956-4626-882D-C092F7042931Q42123260-77AD47DB-C938-40AF-B1E5-87BB2FAA589CQ42429051-ECDF720B-30BE-4504-A048-22A4ADA3AB27Q43842724-1D7C734B-A7BB-4441-85BD-3EE9ECD5E4E7Q47998264-C32C683C-F697-4317-B020-33E55C61A7FFQ48205560-FBDCF6D0-656F-4880-9B21-9D3EC11AE52FQ48234912-5C60EF3A-6F34-44AB-B829-7A842B3EC106Q50003210-3433D393-C8A3-4EA3-A6A8-677411F9E8E8Q50064748-2304E589-7256-4053-AA2C-DA7161D556C6Q50115014-11B0A5CC-83EE-4615-BE0F-73A856CD3655Q50133302-465E8A09-B5A3-44F3-AE91-2747849FC2E0Q52618828-B700BFB6-2110-4C14-B3C7-DADEB72FB5A7Q52810295-10F38EF3-3AC8-4A09-A9F3-ABB243974D6EQ54284515-0CE29B6E-AB04-4C92-A39E-A3FD0EC7CE24Q55005107-DBAE5B42-9C7B-4D32-9E62-E1B937568367Q55041956-73FA01A7-6327-4BD8-BCB8-B0146650CCE7Q55284289-601B35A4-5D9B-44A8-AA54-4C9C2A0CE335Q55427566-E4C1038C-F45E-437D-9344-90C0D06B5F8D
P2860
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A high frequency of activating ...... apillary urothelial carcinoma.
@ast
A high frequency of activating ...... apillary urothelial carcinoma.
@en
type
label
A high frequency of activating ...... apillary urothelial carcinoma.
@ast
A high frequency of activating ...... apillary urothelial carcinoma.
@en
prefLabel
A high frequency of activating ...... apillary urothelial carcinoma.
@ast
A high frequency of activating ...... apillary urothelial carcinoma.
@en
P2093
P1476
A high frequency of activating ...... apillary urothelial carcinoma.
@en
P2093
Amy Donahue
Christine E Sheehan
Doron Lipson
Elaine Labrecque
Garrett Frampton
Gary Palmer
Geneva Young
Geoff A Otto
Jeffrey S Ross
P356
10.1158/1078-0432.CCR-13-1992
P407
P577
2013-11-05T00:00:00Z